

=> d his

(FILE 'HOME' ENTERED AT 14:30:58 ON 28 FEB 2007)

FILE 'CAPLUS' ENTERED AT 14:31:09 ON 28 FEB 2007

L1 16963 S (CHEMILUMINESCENT OR LUMINOL OR LUCIGENIN OR LOPHINE OR ACRID
L2 27 S L1 AND (ENERGY ACCEPTOR OR PHOTOCHROMIC)
L3 5 S L2 AND (BIOLOGICALLY ACTIVE OR DRUG OR PHARMACEUTICAL)

=> d que l3 stat

L1 16963 SEA FILE=CAPLUS ABB=ON PLU=ON (CHEMILUMINESCENT OR LUMINOL
OR LUCIGENIN OR LOPHINE OR ACRIDINIUM OR PHTHALHYDRAZIDE)
L2 27 SEA FILE=CAPLUS ABB=ON PLU=ON L1 AND (ENERGY ACCEPTOR OR
PHOTOCHROMIC)
L3 5 SEA FILE=CAPLUS ABB=ON PLU=ON L2 AND (BIOLOGICALLY ACTIVE OR
DRUG OR PHARMACEUTICAL)

=> d 1-5 bib abs

L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:325744 CAPLUS
DN 142:397734
TI Preparation of prodrugs containing chemiluminescent and
photochromic moieties for selective drug delivery
IN Mills, Randell L.; Wu, Guo-Zhang
PA USA
SO U.S. Pat. Appl. Publ., 199 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 2005080260	A1	20050414	US 2004-828558	20040421
PRAI	US 2003-464354P	P	20030422		
GI					

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to a method of synthesis of a chemical compound (I) having the formula A-B-C that may serve for applications such as drug delivery, where A is a chemiluminescent, moiety, B is a photochromic moiety, and C is a biol. active moiety where A-B-C may serve as a prodrug. Novel synthetic methods of the present invention to form the prodrug comprised the steps of (1) forming a benzophenone, (2) forming a diaryl ethylene, (3) attaching a phthalimide moiety to at least one of the aryl groups of the ethylene to form a phthalimide-ethylene conjugate, (4) condensing two ethylene-phthalimide conjugates to form a phthalimide-pentadiene conjugate, (5) converting the phthalimide to the phthalhydrazide by reaction with hydrazine to form a carrier compound according to the present invention, and (6) reacting the carrier compound with an nucleophilic moiety of the drug to form the corresponding prodrug. Alternatively the carrier can be prepared by using the halo-substituted diaryl ethylene to make the corresponding cationic leuco dye-like compound with known methods. The cationic compound then is protected by reacting with a nucleophile and coupled with the aminophthalimide by palladium-catalyzed amination to form the protected phthalimide-pentadiene conjugate. The latter is refluxed with hydrazine to convert its phthalimide to the phthalhydrazide and acidified to give the carrier. An addnl. aspect of the present invention relates to the use of these compds. as antiviral agents for the treatment of viral infections such as HIV and as anticancer agents for the treatment of cancers such as bowel, lung, and breast cancer.

L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:356146 CAPLUS

DN 141:301244

TI Synthesis and evaluation of novel prodrugs of foscarnet and dideoxycytidine with a universal carrier compound comprising a chemiluminescent and a photochromic conjugate

AU Mills, Randell; Wu, Guo Zhang

CS Luminide Pharmaceutical Corporation, Cranbury, NJ, 08512, USA

SO Journal of Pharmaceutical Sciences (2004), 93(5), 1320-1336

CODEN: JPMSAE; ISSN: 0022-3549

PB Wiley-Liss, Inc.

DT Journal

LA English

AB To facilitate intracellular delivery of hydrophilic drugs, a general lipophilic carrier mol. was designed and synthesized. The carrier comprised a chemiluminescent-photochromic conjugate that potentiates diffusion across cell membranes to enhance intracellular uptake of the drug. The designed mechanism involves activation of the chemiluminescent moiety by intracellular oxygen free radicals and intermol. energy transfer of the excited state energy to the photochromic moiety to result in release of the drug to allow the desired pharmacol. effect to occur. Prodrugs of foscarnet and dideoxycytidine with several carriers caused suppression of a human immunodeficiency virus infection in human cultured macrophages that was up to five times more effective than the drug alone. Successful in vivo efficacy testing of prodrug has been accomplished by demonstrating the suppression of a retroviral infection of Friend leukemia virus in mice. Acute toxicity studies of the carrier indicated that it was nontoxic.

RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2001:613460 CAPLUS

DN 136:212591

TI Measurement of proteases using chemiluminescence-resonance-energy-transfer chimaeras between green fluorescent protein and aequorin

AU Waud, Jonathan P.; Fajardo, Alexandra Bermudez; Sudhaharan, Thankiah; Trimby, Andrew R.; Jeffery, Jinny; Jones, Ann; Campbell, Anthony K.

CS Department of Medical Biochemistry, Cardiff and Vale NHS Trust, Llandough Hospital, Penarth, CF64 2XX, UK

SO Biochemical Journal (2001), 357(3), 687-697

CODEN: BIJOAK; ISSN: 0264-6021

PB Portland Press Ltd.

DT Journal

LA English


AB Homogeneous assays, without a separation step, are essential for measuring chemical events in live cells and for drug discovery screens, and are desirable for making measurements in cell exts. or clin. samples. Here we demonstrate the principle of chemiluminescence resonance energy transfer (CRET) as a homogeneous assay system, using two proteases as models, one extracellular (α -thrombin) and the other intracellular (caspase-3). Chimaeras were engineered with aequorin as the chemiluminescent energy donor and green fluorescent protein (GFP) or enhanced GFP as the energy acceptors, with a protease linker (6 or 18 amino acid residues) recognition site between the donor and acceptor. Flash chemiluminescent spectra (20-60 s) showed that the spectra of chimaeras matched GFP, being similar to that of luminous jellyfish, justifying their designation as "Rainbow" proteins. Addition of the protease shifted the emission spectrum to that of aequorin in a time- and dose-dependent manner. Separation of the proteolyzed fragments showed that the ratio of green to blue light matched the extent of proteolysis. The caspase-3 Rainbow protein was able to provide information on the specificity of caspases in vitro and in vivo. It was also able to monitor caspase-3 activation in cells provoked into apoptosis by staurosporine (1 or 2 μ M). CRET can also monitor GFP fluor formation. The signal-to-noise ratio of our Rainbow proteins is superior to that of fluorescence resonance energy transfer, providing a potential platform for measuring agents that interact with the reactive site between the donor and acceptor.

RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1995:705748 CAPLUS
 DN 123:296612
 TI Prodrugs for selective drug delivery
 IN Mills, Randell L.
 PA USA
 SO U.S., 76 pp. Cont.-in-part of U.S. Ser. No. 948,326, abandoned.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5428163	A	19950627	US 1989-446439	19891204
	US 5773592	A	19980630	US 1995-450672	19950530
	US 6555663	B1	20030429	US 2000-733809	20001208
PRAI	US 1986-948326	B2	19861231		
	US 1988-175970	B2	19880331		
	US 1989-446439	A1	19891204		
	US 1995-450672	A1	19950530		
	US 1998-107338	B1	19980630		

GI



AB A class of pharmaceutical agents which react directly with electron carriers or with reactive species produced by electron transport to release a pharmacol. active mol. comprises (A) a functionality which is activatable by the environment [e.g. via an electron transfer functionality (D)] and capable of transferring energy from its excited state to (B) an energy acceptor which then achieves an excited state and relaxes through heterolytic cleavage of the covalent bond between B and (C), a drug moiety which is thereby released into the intracellular compartment. This type of prodrug, with structure ABC, DABC, AD BC, or AB(D)C, is designated a luminide. A is especially a chemiluminescent mol., e.g. a triarylmethane dye; B is a photochromic mol., e.g. any of several types of cationic dyes; C is a drug mol. with bleaching activity toward B or a

drug mol. conjugated to a bleaching nucleophilic group; D is a mol. able to undergo redox reactions. Thus, MTL J-1 (I), administered (10 μ mol) to mice infected with Raucher spleen focus-forming virus (a model for HIV infection), prevented development of splenomegaly. I was prepared from p-dimethylaminobenzoic acid, N-ethyl-N-(2-chloroethyl)aniline, and N-(4-aminobutyl)-N-ethylisoluminol in several steps including dimerization.

L3 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1990:111395 CAPLUS
DN 112:111395
TI Fluorogenic reaction between adenine derivatives and chloroacetaldehyde
and its application to the determination of 9-(2-chloro-6-
fluorobenzyl)adenine in human plasma
AU Matuszewski, Bogdan K.; Bayne, William F.
CS Merck Sharp and Dohme Res. Lab., West Point, PA, 19486, USA
SO Analytica Chimica Acta (1989), 227(1), 189-202
CODEN: ACACAM; ISSN: 0003-2670
DT Journal
LA English
AB A sensitive (1 ng/mL) liquid chromatog. method with fluorescence detection
is described for the determination of arprinocid and analogous compds. in human
plasma. The method is based on chemical derivatization with
chloroacetaldehyde to form highly fluorescent derivs. Extraction of the
drug from plasma and separation of the derivative from the reaction mixture
are accomplished by solid-phase extraction with 2 silica cartridges. The
effects of pH, solvent, and concentration of the reagents of the efficiency of
derivatization were studied. The assay in plasma was validated in the
1-50 ng/mL range. The fluorescent derivs. were synthesized and fully
characterized. The derivs. were also found to be efficient as
energy acceptors in the oxalate ester/H2O2
chemiluminescent system.

=> FIL STNGUIDE

FILE 'STNGUIDE' ENTERED AT 14:35:06 ON 28 FEB 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Feb 23, 2007 (20070223/UP).

=> fil capl

FILE 'CAPLUS' ENTERED AT 14:36:44 ON 28 FEB 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 28 Feb 2007 VOL 146 ISS 10
FILE LAST UPDATED: 27 Feb 2007 (20070227/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

'FIONA' IS DEFAULT FORMAT FOR 'CAPLUS' FILE

=> => d que 17 stat

L4	94	SEA	FILE=CAPLUS	ABB=ON	PLU=ON	("MILLS RANDELL"/AU OR "MILLS RANDELL L"/AU)
L5	16	SEA	FILE=CAPLUS	ABB=ON	PLU=ON	"WU GUO ZHANG"/AU
L6	108	SEA	FILE=CAPLUS	ABB=ON	PLU=ON	L4 OR L5
L7	4	SEA	FILE=CAPLUS	ABB=ON	PLU=ON	L6 AND PRODRUG

=> d 1-4 bib abs

L7 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:325744 CAPLUS
DN 142:397734
TI Preparation of prodrugs containing chemiluminescent and
photochromic moieties for selective drug delivery
IN Mills, Randell L.; Wu, Guo-Zhang
PA USA
SO U.S. Pat. Appl. Publ., 199 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	US 2005080260	A1	20050414	US 2004-828558	20040421
PRAI	US 2003-464354P	P	20030422		
GI					

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to a method of synthesis of a chemical compound (I) having the formula A-B-C that may serve for applications such as drug delivery, where A is a chemiluminescent, moiety, B is a photochromic moiety, and C is a biol. active moiety where A-B-C may serve as a prodrug. Novel synthetic methods of the present invention to form the prodrug comprised the steps of (1) forming a benzophenone, (2) forming a diaryl ethylene, (3) attaching a phthalimide moiety to at least one of the aryl groups of the ethylene to form a phthalimide-ethylene conjugate, (4) condensing two ethylene-phthalimide conjugates to form a phthalimide-pentadiene conjugate, (5) converting the phthalimide to the phthalhydrazide by reaction with hydrazine to form a carrier compound according to the present invention, and (6) reacting the carrier compound with an nucleophilic moiety of the drug to form the corresponding prodrug. Alternatively the carrier can be prepared by using the halo-substituted diaryl ethylene to make the corresponding cationic leuco dye-like compound with known methods. The cationic compound then is protected by reacting with a nucleophile and coupled with the aminophthalimide by palladium-catalyzed amination to form the protected phthalimide-pentadiene conjugate. The latter is refluxed with hydrazine to convert its phthalimide to the phthalhydrazide and acidified to give the carrier. An addnl. aspect of the present invention relates to the use of these compds. as antiviral agents for the treatment of viral infections such as HIV and as anticancer agents for the treatment of cancers such as bowel, lung, and breast cancer.

L7 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:356146 CAPLUS

DN 141:301244

TI Synthesis and evaluation of novel prodrugs of foscarnet and dideoxycytidine with a universal carrier compound comprising a chemiluminescent and a photochromic conjugate

AU Mills, Randell; Wu, Guo Zhang

CS Luminide Pharmaceutical Corporation, Cranbury, NJ, 08512, USA

SO Journal of Pharmaceutical Sciences (2004), 93(5), 1320-1336

CODEN: JPMSAE; ISSN: 0022-3549

PB Wiley-Liss, Inc.

DT Journal

LA English

AB To facilitate intracellular delivery of hydrophilic drugs, a general lipophilic carrier mol. was designed and synthesized. The carrier comprised a chemiluminescent-photochromic conjugate that potentiates diffusion across cell membranes to enhance intracellular uptake of the drug. The designed mechanism involves activation of the chemiluminescent moiety by intracellular oxygen free radicals and intermol. energy transfer of the excited state energy to the photochromic moiety to result in release of the drug to allow the desired pharmacol. effect to occur. Prodrugs of foscarnet and dideoxycytidine with several carriers caused suppression of a human immunodeficiency virus infection in human cultured macrophages that was up to five times more effective than the drug alone. Successful in vivo efficacy testing of prodrug has been accomplished by demonstrating the suppression of a retroviral infection of Friend leukemia virus in mice. Acute toxicity studies of the carrier indicated that it was nontoxic.

RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2001:923643 CAPLUS
 DN 136:42881
 TI Prodrugs for selective drug delivery comprising a photochromic moiety and thermochromic moiety
 IN Mills, Randell L.
 PA USA
 SO PCT Int. Appl., 19 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001095944	A2	20011220	WO 2001-US18869	20010612
	WO 2001095944	A3	20020808		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2001066861	A5	20011224	AU 2001-66861	20010612
	US 2003228644	A1	20031211	US 2002-316989	20021210
	US 7015352	B2	20060321		
PRAI	US 2000-211036P	P	20000612		
	WO 2001-US18869	W	20010612		

AB Prodrug compds. are disclosed capable of permeating a desired biol. compartment and releasing a biol. active mol. in active form to effect a therapeutic functional change in the compartment to which it is introduced. An exemplary luminide is 1-phosphonoformate,1,5,di-(p-N-ethyl-N-ethylaminophenyl)-1,5-bis-(p-N,N-dimethylaniline)-1,3-pentadiene.

L7 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1995:705748 CAPLUS
 DN 123:296612
 TI Prodrugs for selective drug delivery
 IN Mills, Randell L.
 PA USA
 SO U.S., 76 pp. Cont.-in-part of U.S. Ser. No. 948,326, abandoned.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5428163	A	19950627	US 1989-446439	19891204
	US 5773592	A	19980630	US 1995-450672	19950530
	US 6555663	B1	20030429	US 2000-733809	20001208
PRAI	US 1986-948326	B2	19861231		
	US 1988-175970	B2	19880331		
	US 1989-446439	A1	19891204		
	US 1995-450672	A1	19950530		
	US 1998-107338	B1	19980630		

GI



AB A class of pharmaceutical agents which react directly with electron carriers or with reactive species produced by electron transport to release a pharmacol. active mol. comprises (A) a functionality which is activatable by the environment [e.g. via an electron transfer functionality (D)] and capable of transferring energy from its excited state to (B) an energy acceptor which then achieves an excited state and relaxes through heterolytic cleavage of the covalent bond between B and (C), a drug moiety which is thereby released into the intracellular compartment. This type of prodrug, with structure ABC, DABC, ADBC, or AB(D)C, is designated a luminide. A is especially a chemiluminescent mol., e.g. a triarylmethane dye; B is a photochromic mol., e.g. any of several types of cationic dyes; C is a drug mol. with bleaching activity toward B or a drug mol. conjugated to a bleaching nucleophilic group; D is

a mol. able to undergo redox reactions. Thus, MTL J-1 (I), administered (10 μ mol) to mice infected with Raucher spleen focus-forming virus (a model for HIV infection), prevented development of splenomegaly. I was prepared from p-dimethylaminobenzoic acid, N-ethyl-N-(2-chloroethyl)aniline, and N-(4-aminobutyl)-N-ethylisoluminol in several steps including dimerization.

=> d his full

(FILE 'HOME' ENTERED AT 14:30:58 ON 28 FEB 2007)

FILE 'CAPLUS' ENTERED AT 14:31:09 ON 28 FEB 2007

L1 16963 SEA ABB=ON PLU=ON (CHEMILUMINESCENT OR LUMINOL OR LUCIGENIN
OR LOPHINE OR ACRIDINIUM OR PHTHALHYDRAZIDE)
L2 27 SEA ABB=ON PLU=ON L1 AND (ENERGY ACCEPTOR OR PHOTOCHROMIC)
L3 5 SEA ABB=ON PLU=ON L2 AND (BIOLOGICALLY ACTIVE OR DRUG OR
PHARMACEUTICAL)
D QUE L3 STAT
D 1-5 BIB ABS

FILE 'STNGUIDE' ENTERED AT 14:35:06 ON 28 FEB 2007

FILE 'CAPLUS' ENTERED AT 14:36:44 ON 28 FEB 2007

E MILLS RANDELL/AU
L4 94 SEA ABB=ON PLU=ON ("MILLS RANDELL"/AU OR "MILLS RANDELL
L"/AU)
E WU GUO ZHANG/AU
L5 16 SEA ABB=ON PLU=ON "WU GUO ZHANG"/AU
L6 108 SEA ABB=ON PLU=ON L4 OR L5
L7 4 SEA ABB=ON PLU=ON L6 AND PRODRUG
D QUE L7 STAT
D 1-4 BIB ABS

FILE HOME

FILE CAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 28 Feb 2007 VOL 146 ISS 10

FILE LAST UPDATED: 27 Feb 2007 (20070227/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

FILE STNGUIDE

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Feb 23, 2007 (20070223/UP).

=> => d que 18 stat

L8 1 SEA FILE=CAPLUS ABB=ON PLU=ON BENZOPHENONE AND (DIARYL
ETHYLENE OR DIARYLETHYLENE) AND (PHALHYDRAZIDE OR PHTHALIMIDE
OR #PHTHALIC)

=> d bib abs

L8 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:325744 CAPLUS
DN 142:397734
TI Preparation of prodrugs containing chemiluminescent and photochromic
moieties for selective drug delivery
IN Mills, Randell L.; Wu, Guo-Zhang
PA USA
SO U.S. Pat. Appl. Publ., 199 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 2005080260	A1	20050414	US 2004-828558	20040421
PRAI	US 2003-464354P	P	20030422		

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to a method of synthesis of a chemical compound (I) having the formula A-B-C that may serve for applications such as drug delivery, where A is a chemiluminescent, moiety, B is a photochromic moiety, and C is a biol. active moiety where A-B-C may serve as a prodrug. Novel synthetic methods of the present invention to form the prodrug comprised the steps of (1) forming a benzophenone, (2) forming a diaryl ethylene, (3) attaching a phthalimide moiety to at least one of the aryl groups of the ethylene to form a phthalimide-ethylene conjugate, (4) condensing two ethylene-phthalimide conjugates to form a phthalimide-pentadiene conjugate, (5) converting the phthalimide to the phthalhydrazide by reaction with hydrazine to form a carrier compound according to the present invention, and (6) reacting the carrier compound with an nucleophilic moiety of the drug to form the corresponding prodrug. Alternatively the carrier can be prepared by using the halo-substituted diaryl ethylene to make the corresponding cationic leuco dye-like compound with known methods. The cationic compound then is protected by reacting with a nucleophile and coupled with the aminophthalimide by palladium-catalyzed amination to form the protected phthalimide-pentadiene conjugate. The latter is refluxed with hydrazine to convert its phthalimide to the phthalhydrazide and acidified to give the carrier. An addnl. aspect of the present invention relates to the use of these compds. as antiviral agents for the treatment of viral infections such as HIV and as anticancer agents for the treatment of cancers such as bowel, lung, and breast cancer.

=> d his full

(FILE 'HOME' ENTERED AT 14:30:58 ON 28 FEB 2007)

FILE 'CAPLUS' ENTERED AT 14:31:09 ON 28 FEB 2007

L1 16963 SEA ABB=ON PLU=ON (CHEMILUMINESCENT OR LUMINOL OR LUCIGENIN
OR LOPHINE OR ACRIDINIUM OR PHTHALHYDRAZIDE)
L2 27 SEA ABB=ON PLU=ON L1 AND (ENERGY ACCEPTOR OR PHOTOCHROMIC)
L3 5 SEA ABB=ON PLU=ON L2 AND (BIOLOGICALLY ACTIVE OR DRUG OR
PHARMACEUTICAL)
D QUE L3 STAT
D 1-5 BIB ABS

FILE 'STNGUIDE' ENTERED AT 14:35:06 ON 28 FEB 2007

FILE 'CAPLUS' ENTERED AT 14:36:44 ON 28 FEB 2007

E MILLS RANDELL/AU
L4 94 SEA ABB=ON PLU=ON ("MILLS RANDELL"/AU OR "MILLS RANDELL
L"/AU)
E WU GUO ZHANG/AU
L5 16 SEA ABB=ON PLU=ON "WU GUO ZHANG"/AU
L6 108 SEA ABB=ON PLU=ON L4 OR L5
L7 4 SEA ABB=ON PLU=ON L6 AND PRODRUG
D QUE L7 STAT
D 1-4 BIB ABS
L8 1 SEA ABB=ON PLU=ON BENZOPHENONE AND (DIARYL ETHYLENE OR
DIARYLETHYLENE) AND (PHALHYDRAZIDE OR PHTHALIMIDE OR #PHTHALIC)
D QUE L8 STAT
D BIB ABS

FILE HOME

FILE CAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 28 Feb 2007 VOL 146 ISS 10
FILE LAST UPDATED: 27 Feb 2007 (20070227/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

FILE STNGUIDE
FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Feb 23, 2007 (20070223/UP).

=> => log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

39.08

83.04

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.90	-7.80

STN INTERNATIONAL LOGOFF AT 14:40:32 ON 28 FEB 2007